Business
Amylyx is a clinical-stage pharmaceutical company developing therapies for communities with high unmet medical needs, with programs in endocrine conditions and neurodegenerative diseases.
Amylyx revenue fell to zero, but net loss narrowed to $144.7M and equity rose to $305.3M.
The read at a glance✓ Audited against SEC data
- Business mix — Clinical-stage pharma pipelineNote
- Revenue — Revenue fell to zeroWatch
- Profitability — Net loss narrowed to $144.7MNote
- Cash — Free cash flow negative $123.5MNote
- Equity — Equity rose 85.3%OK
- Insiders — 1 buy / 25 sellsWatch
- Accounting — Altman-Z grey; other scores unavailableNote
Leadership changes
From Amylyx Pharmaceuticals, Inc.'s own filings, the day they're filed.
- Bernhardt Zeiher · director · appointment
- Paul Fonteyne · Chief Medical Officer · appointment
Latest filings
- 8-K · Company announcement2026-08-20
- 8-K · Company announcement2026-08-18
- 8-K · Company announcement2026-08-18
- 8-K · Company announcement2026-08-06
- 10-Q · Quarterly report2026-08-06
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Amylyx Pharmaceuticals, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.